Cancer - APEC1621F: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
Condition or Therapy:
Solid tumors, non-Hodgkin lymphomas and histiocytic disorders
What is the goal of this study?
The goal of this study is to see how well genetically targeted medication works on patients with specific genetic mutations, specifically in patients with solid tumors, non-Hodgkin lymphomas and histiocytic disorders. This study will also look at patients' progress after treatment and how well patients tolerate the study's drug. This study is one of many studies that are focused on treating cancer using genomics.
Who can join the study?
This study may be a good fit for children and young adults who are:
- Enrolled in study APEC1621SC
- Between 12 months and 21 years old
You can read more about the eligibility criteria for this study on clinicaltrials.gov.
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for your child.
What will happen if my child takes part in this study?
Participants in the study will be asked to:
- Be enrolled in study APEC1621SC, the screening protocol for all MATCH sub-trials
- Take the study drug once a day
- Have their disease evaluated every 56 days
Who can I contact for more information?
Please email the research coordinator or call the study team at (206) 987-2106 for more information about this study.